GFAP and Alzheimer disease: These results are similar to a recent study by Chiotis et al. who found a negative correlation between plasma GFAP concentrations and a PET biomarker of reactive astrocytosis; 11C-deuterium-L-deprenyl (11C-DED), in patients with sporadic AD (43).